The ARCTIC REWIND project (NCT01881308) was a phase 4 study that investigated the withdrawal of disease-modifying antirheumatic drugs in rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we were delighted to speak to Dr. Siri Lillegraven (Diakonhjemmet Hospital, Oslo, Norway) to discuss how achievable drug free remission is as a treatment goal in RA, an overview of and the findings from the ARCTIC REWIND project and what further studies are needed.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial.‘ (Abstract number: 2013) was presented at the ACR Convergence, November 10–14, 2022.
- How achievable a treatment goal is drug free remission in rheumatoid arthritis? (0:22)
- Could you give us a brief overview of the ARCTIC REWIND project? (1:16)
- What was the primary endpoint and how well was it achieved? (2:22)
- What was the key take-home message of these findings? (3:31)
- What questions remain unanswered and what further studies are planned? (4:26)
Disclosures: Siri Lillegraven has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Kim Lauper, ACR 2022: Safety of JAK-inhibitors in rheumatoid arthritis in a real-world population
The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. Kim Lauper (Geneva University Hospitals, Genéve, Switzerland) around her study assessing the safety of JAKis […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!